Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad) Free AUPH Stock Alerts

Aurinia Pharmaceuticals (AUPH) Financials

Aurinia Pharmaceuticals logo
$11.38 -0.05 (-0.39%)
Closing price 03:59 PM Eastern
Extended Trading
$11.38 -0.01 (-0.09%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Aurinia Pharmaceuticals

Annual Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -23 -71 -54 -88 -103 -181 -108 -78 5.75
Consolidated Net Income / (Loss)		 -23 -71 -53 -88 -103 -181 -108 -78 5.75
Net Income / (Loss) Continuing Operations		 -23 -71 -54 -88 -103 -181 -108 -78 5.75
Total Pre-Tax Income 		-23 -71 -53 -88 -103 -180 -106 -77 7.45
Total Operating Income		 -25 -47 -55 -91 -104 -181 -111 -92 -4.69
Total Gross Profit		 0.00 0.42 0.46 0.32 50 45 128 161 207
Total Revenue		 0.17 0.42 0.46 0.32 50 46 134 176 235
Operating Revenue		 0.01 - 0.46 0.32 50 46 134 176 235
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 1.09 5.66 14 28
Operating Cost of Revenue		 0.00 - - 0.00 0.00 1.09 5.66 14 28
Total Operating Expenses		 25 47 57 91 154 225 240 253 212
Selling, General & Admin Expense		 6.97 12 14 22 97 174 196 195 172
Research & Development Expense		 15 34 41 53 50 51 45 50 21
Other Operating Expenses / (Income)		 2.21 -0.20 -0.67 15 6.81 0.57 -1.52 8.38 -4.35
Restructuring Charge		 - - - - - - 0.00 0.00 23
Total Other Income / (Expense), net		 1.73 -24 2.23 2.70 1.52 0.53 5.12 14 12
Interest Expense		 - - - - - 0.00 0.00 2.78 4.84
Interest & Investment Income		 - - 2.23 2.70 1.52 0.53 5.12 17 17
Income Tax Expense		 - - 0.07 0.14 -0.09 0.76 1.83 0.55 1.70
Basic Earnings per Share		 ($0.66) ($0.92) ($0.63) ($0.95) ($0.87) ($1.40) ($0.76) ($0.54) $0.04
Weighted Average Basic Shares Outstanding		 - 84.05M 84.78M 93.02M 118.47M 129.37M 141.92M 143.24M 143.06M
Diluted Earnings per Share		 ($0.66) ($0.92) ($0.63) ($0.95) ($0.87) ($1.40) ($0.76) ($0.54) $0.04
Weighted Average Diluted Shares Outstanding		 - 84.05M 84.78M 93.02M 118.47M 129.37M 141.92M 143.24M 146.19M
Weighted Average Basic & Diluted Shares Outstanding		 - 84.05M 84.78M 93.02M 118.47M 129.37M 142.58M 144.62M 137.34M

Quarterly Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -26 -12 -13 -27 -11 0.72 15 0.96 23 22
Consolidated Net Income / (Loss)		 -26 -26 -11 -13 -27 -11 0.72 14 1.43 23 22
Net Income / (Loss) Continuing Operations		 -26 -26 -11 -13 -27 -11 0.72 14 1.43 23 22
Total Pre-Tax Income 		-25 -26 -12 -13 -26 -10 1.48 15 1.17 24 22
Total Operating Income		 -28 -30 -16 -16 -30 -13 -1.51 12 -1.67 22 20
Total Gross Profit		 27 34 40 48 40 43 48 62 54 54 63
Total Revenue		 28 34 41 55 45 50 57 68 60 62 70
Operating Revenue		 28 34 41 55 45 50 57 68 60 62 70
Total Cost of Revenue		 1.36 0.42 1.56 6.77 5.40 7.75 8.91 6.04 5.55 8.57 7.12
Operating Cost of Revenue		 1.36 0.42 1.56 6.77 5.40 7.75 8.91 6.04 5.55 8.57 7.12
Total Operating Expenses		 55 64 56 64 69 56 50 50 56 32 43
Selling, General & Admin Expense		 47 50 47 48 50 48 45 42 37 20 26
Research & Development Expense		 9.87 13 13 14 10 5.55 4.08 3.05 8.11 5.74 7.43
Other Operating Expenses / (Income)		 -2.17 0.29 -3.63 2.65 9.07 -4.13 -0.29 4.57 -4.51 4.43 9.25
Restructuring Charge		 - 0.00 0.00 0.00 - 6.68 1.07 0.00 15 1.53 0.11
Total Other Income / (Expense), net		 2.91 3.81 4.04 3.11 3.26 3.24 2.99 3.06 2.84 2.50 2.07
Interest Expense		 - 0.00 0.07 1.40 1.31 1.28 1.20 1.21 1.15 1.07 1.12
Interest & Investment Income		 2.91 3.81 4.10 4.51 4.57 4.53 4.19 4.27 3.99 3.57 3.19
Income Tax Expense		 0.86 0.44 -0.64 0.30 0.46 0.74 0.76 0.46 -0.26 1.01 0.64
Basic Earnings per Share		 ($0.18) ($0.18) ($0.08) ($0.09) ($0.19) ($0.07) $0.01 $0.10 - $0.17 $0.16
Weighted Average Basic Shares Outstanding		 141.92M 142.64M 142.78M 142.85M 143.24M 144.01M 143.33M 143.05M 143.06M 138.92M 134.87M
Diluted Earnings per Share		 ($0.18) ($0.18) ($0.08) ($0.09) ($0.19) ($0.07) $0.01 $0.10 - $0.16 $0.16
Weighted Average Diluted Shares Outstanding		 141.92M 142.64M 142.78M 142.85M 143.24M 144.01M 144.11M 145.65M 146.19M 143.20M 137.53M
Weighted Average Basic & Diluted Shares Outstanding		 142.58M 143.03M 143.42M 143.61M 144.62M 143.02M 142.99M 143.18M 137.34M 135.10M 131.63M

Annual Cash Flow Statements for Aurinia Pharmaceuticals

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 44 126 -48 188 -34 -40 -138 -45 35
Net Cash From Operating Activities		 -21 -41 -52 -64 -70 -158 -80 -33 44
Net Cash From Continuing Operating Activities		 -21 -41 -52 -64 -70 -158 -80 -33 44
Net Income / (Loss) Continuing Operations		 -23 -71 -53 -88 -103 -181 -108 -78 5.75
Consolidated Net Income / (Loss)		 -23 -71 -53 -88 -103 -181 -108 -78 5.75
Depreciation Expense		 - 0.02 0.02 0.03 1.37 2.76 2.71 12 19
Amortization Expense		 1.29 -0.12 1.29 1.14 - 0.66 -1.57 -12 -13
Non-Cash Adjustments To Reconcile Net Income		 1.25 30 6.15 22 21 42 34 51 26
Changes in Operating Assets and Liabilities, net		 - - -6.00 2.03 10 -22 -6.82 -5.61 5.45
Net Cash From Investing Activities		 31 -8.00 -0.07 7.78 -158 -104 -61 -6.71 39
Net Cash From Continuing Investing Activities		 31 -8.00 -0.07 7.78 -158 -104 -61 -6.71 39
Purchase of Property, Plant & Equipment		 - -0.03 -0.07 -0.09 -7.34 -1.50 -0.29 -0.72 -0.28
Purchase of Investments		 - -98 -36 0.00 -203 -445 -524 -524 -546
Sale and/or Maturity of Investments		 31 90 36 7.88 52 354 464 529 585
Other Investing Activities, net		 - - - 0.00 0.00 -12 -0.66 -12 -0.04
Net Cash From Financing Activities		 34 175 4.01 244 194 221 2.43 -5.13 -49
Net Cash From Continuing Financing Activities		 34 166 4.01 244 194 221 2.43 -5.13 -49
Repurchase of Common Equity		 - - - - - - 0.00 0.00 -40
Issuance of Common Equity		 7.82 162 0.00 223 188 197 1.91 1.85 1.08
Other Financing Activities, net		 - 4.14 4.01 21 6.64 24 0.52 -6.98 -9.94
Cash Income Taxes Paid		 - - 0.00 0.06 0.26 0.26 1.98 0.50 2.18

Quarterly Cash Flow Statements for Aurinia Pharmaceuticals

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 8.12 -5.17 -7.29 -35 2.48 16 -31 3.74 46 -17 -13
Net Cash From Operating Activities		 10 -32 -2.83 -13 14 -19 16 17 30 1.30 44
Net Cash From Continuing Operating Activities		 10 -32 -2.83 -13 14 -19 16 17 30 1.30 44
Net Income / (Loss) Continuing Operations		 -26 -26 -11 -13 -27 -11 0.72 14 1.43 23 22
Consolidated Net Income / (Loss)		 -26 -26 -11 -13 -27 -11 0.72 14 1.43 23 22
Depreciation Expense		 0.22 0.72 0.72 5.26 4.95 4.85 4.84 4.89 4.86 4.86 4.86
Amortization Expense		 -1.56 -2.61 -2.99 -3.24 -3.31 -3.21 -3.13 -3.42 -2.98 -2.66 -2.56
Non-Cash Adjustments To Reconcile Net Income		 5.87 9.68 8.82 12 20 1.27 7.62 13 4.32 0.73 15
Changes in Operating Assets and Liabilities, net		 32 -13 2.12 -14 19 -11 5.78 -12 22 -25 5.73
Net Cash From Investing Activities		 -3.02 25 -5.61 -20 -6.26 49 -39 -11 39 31 -13
Net Cash From Continuing Investing Activities		 -3.02 25 -5.61 -20 -6.26 49 -39 -11 39 31 -13
Purchase of Property, Plant & Equipment		 -0.13 -0.35 -0.18 0.11 -0.30 -0.01 - - -0.28 -0.02 -0.10
Purchase of Investments		 -121 -142 -114 -123 -144 -121 -197 -143 -85 -92 -145
Sale and/or Maturity of Investments		 118 168 121 103 138 171 158 133 124 123 132
Net Cash From Financing Activities		 0.69 1.64 1.14 -2.33 -5.58 -15 -8.27 -2.72 -23 -49 -44
Net Cash From Continuing Financing Activities		 0.69 1.64 1.14 -2.33 -5.58 -15 -8.27 -2.72 -23 -49 -44
Repurchase of Common Equity		 - 0.00 - - - -12 -6.13 - -22 -47 -43
Other Financing Activities, net		 -1.22 1.64 1.14 -2.33 -7.43 -2.75 -2.14 -2.72 -2.33 -2.42 -2.23
Cash Income Taxes Paid		 1.20 0.00 0.28 0.06 0.16 0.00 1.46 - 0.73 0.25 0.82

Annual Balance Sheets for Aurinia Pharmaceuticals

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 57 190 146 324 464 543 471 548 551
Total Current Assets		 40 175 133 315 419 513 443 425 447
Cash & Equivalents		 40 166 118 306 272 232 94 49 83
Short-Term Investments		 0.00 7.83 7.89 0.00 126 234 295 302 275
Accounts Receivable		 0.09 0.11 0.22 0.37 0.00 15 13 24 37
Inventories, net		 - - - 0.00 14 19 25 40 39
Prepaid Expenses		 - 1.68 6.78 8.75 7.17 12 14 9.49 11
Other Current Assets		 - - - - - 0.80 1.33 1.03 1.13
Plant, Property, & Equipment, net		 0.00 0.03 0.04 0.09 4.79 4.42 3.65 3.35 2.73
Total Noncurrent Assets		 17 15 13 9.07 39 26 25 120 101
Noncurrent Note & Lease Receivables		 - - - - - - 0.00 109 92
Intangible Assets		 16 14 13 8.86 9.33 8.40 6.43 4.98 4.36
Other Noncurrent Operating Assets		 1.71 0.45 0.36 0.21 5.74 17 18 6.02 4.89
Total Liabilities & Shareholders' Equity		 57 190 146 324 464 543 471 548 551
Total Liabilities		 21 24 33 26 56 64 65 170 173
Total Current Liabilities		 5.79 8.15 7.26 11 32 41 46 77 98
Accounts Payable		 5.79 7.96 7.07 11 25 35 40 4.33 5.19
Accrued Expenses		 - - - - - - - 50 65
Current Deferred Revenue		 - 0.12 0.12 - - 0.19 3.15 4.81 11
Other Current Liabilities		 - - - 0.12 7.20 5.51 2.97 18 17
Total Noncurrent Liabilities		 50 12 22 14 24 24 19 93 75
Noncurrent Deferred Revenue		 0.68 0.44 0.32 - - - - - 1.70
Other Noncurrent Operating Liabilities		 50 - - 14 24 24 19 93 74
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.97 166 113 299 408 479 405 378 377
Total Preferred & Common Equity		 0.97 166 113 299 408 479 405 378 377
Total Common Equity		 0.97 166 113 299 408 479 405 378 377
Common Stock		 - 499 505 772 984 1,236 1,271 1,321 1,315
Retained Earnings		 - -352 -416 -472 -575 -756 -864 -942 -937
Accumulated Other Comprehensive Income / (Loss)		 - -0.88 -0.81 -0.81 -0.81 -0.85 -1.06 -0.73 -0.65

Quarterly Balance Sheets for Aurinia Pharmaceuticals

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets		 482 488 452 549 555 517 524 549 505 503
Total Current Assets		 453 460 424 416 426 398 410 440 406 409
Cash & Equivalents		 152 86 89 82 46 64 33 37 66 53
Short-Term Investments		 240 291 273 269 292 255 297 312 246 262
Accounts Receivable		 18 42 19 19 38 29 26 36 40 40
Inventories, net		 26 25 32 33 33 40 39 39 46 47
Prepaid Expenses		 17 12 10 11 16 7.65 7.84 14 5.54 6.58
Other Current Assets		 - 3.81 1.23 1.21 1.65 2.00 6.98 2.70 0.78 0.67
Plant, Property, & Equipment, net		 4.18 3.76 3.84 3.65 3.50 3.20 3.04 2.89 2.58 2.42
Total Noncurrent Assets		 25 25 24 129 125 115 111 106 97 91
Noncurrent Note & Lease Receivables		 - - - 117 113 104 101 - 88 83
Intangible Assets		 7.34 6.84 6.10 5.68 5.26 4.76 4.62 4.51 4.16 4.05
Other Noncurrent Operating Assets		 17 18 18 6.23 6.13 5.90 5.16 102 4.78 3.93
Total Liabilities & Shareholders' Equity		 482 488 452 549 555 517 524 549 505 503
Total Liabilities		 58 65 61 157 163 157 159 161 155 167
Total Current Liabilities		 35 42 42 62 74 71 77 79 68 78
Accounts Payable		 32 40 36 41 52 50 56 57 4.22 3.31
Accrued Expenses		 - - - - - - - - 42 50
Current Deferred Revenue		 - - 3.16 3.23 4.66 4.91 4.37 4.30 4.59 5.50
Other Current Liabilities		 2.25 1.64 2.92 17 17 16 16 18 17 20
Total Noncurrent Liabilities		 24 23 19 95 89 86 82 83 86 89
Noncurrent Deferred Revenue		 - - - - - - - - 12 12
Other Noncurrent Operating Liabilities		 24 23 19 95 89 86 82 83 74 77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 424 423 390 392 392 359 365 388 350 335
Total Preferred & Common Equity		 424 423 390 392 392 359 365 388 350 335
Total Common Equity		 424 423 390 392 392 359 365 388 350 335
Common Stock		 1,255 1,263 1,282 1,295 1,308 1,313 1,318 1,326 1,264 1,228
Retained Earnings		 -829 -838 -891 -902 -915 -953 -952 -938 -913 -892
Accumulated Other Comprehensive Income / (Loss)		 -1.85 -1.53 -0.99 -1.02 -0.95 -0.85 -0.86 -0.39 -0.83 -0.91

Annual Metrics And Ratios for Aurinia Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 141.62% 10.77% -31.32% 15,660.38% -9.00% 193.89% 30.95% 33.97%
EBITDA Growth		 0.00% -222.13% 23.93% -66.47% -14.64% -72.29% 37.77% 16.45% 102.20%
EBIT Growth		 0.00% -203.89% 21.97% -64.63% -14.68% -73.30% 38.32% 17.74% 94.89%
NOPAT Growth		 0.00% -87.27% -17.86% -64.63% -14.68% -73.30% 38.32% 17.74% 94.36%
Net Income Growth		 0.00% -203.89% 25.02% -66.52% -16.17% -76.24% 40.22% 27.88% 107.37%
EPS Growth		 0.00% -39.39% 31.52% -50.79% 8.42% -60.92% 45.71% 28.95% 107.41%
Operating Cash Flow Growth		 0.00% -98.33% -25.36% -23.20% -9.87% -125.73% 49.57% 57.93% 232.66%
Free Cash Flow Firm Growth		 0.00% 0.00% 45.44% -1.04% -49.64% -135.99% 47.53% 6.98% 106.16%
Invested Capital Growth		 0.00% 120.34% 58.84% -159.38% -101.63% 186.99% 23.30% 69.92% -30.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -36.86% 3.90% 10.49% 6.70%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -16.09% 2.23% 1.51% 107.73%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -15.79% 3.97% -1.75% 85.66%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -15.79% 3.97% -1.75% 84.18%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -16.21% 6.30% -1.07% 125.51%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -14.75% 7.32% -1.89% 126.67%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -22.65% 31.38% 10.35% 55.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.28% -8.20% 153.03%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 10.54% -65.70% -48.93% -51.59%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.58% 100.00% 100.00% 100.00% 100.00% 97.61% 95.77% 91.94% 87.99%
EBITDA Margin		 -12,720.23% -16,958.85% -11,647.30% -28,230.19% -205.35% -388.80% -82.32% -52.52% 0.86%
Operating Margin		 -14,466.47% -11,212.44% -11,930.89% -28,598.43% -208.09% -396.31% -83.17% -52.24% -1.99%
EBIT Margin		 -13,465.32% -16,935.89% -11,930.89% -28,598.43% -208.09% -396.31% -83.17% -52.24% -1.99%
Profit (Net Income) Margin		 -13,465.32% -16,935.89% -11,464.15% -27,794.03% -204.88% -396.81% -80.71% -44.45% 2.45%
Tax Burden Percent		 100.00% 100.00% 100.14% 100.16% 99.91% 100.42% 101.72% 100.71% 77.23%
Interest Burden Percent		 100.00% 100.00% 95.96% 97.03% 98.55% 99.71% 95.41% 84.49% -158.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.77%
Return on Invested Capital (ROIC)		 0.00% 0.00% -379.84% -2,508.77% 0.00% 0.00% -537.06% -296.40% -15.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -368.67% -2,496.60% 0.00% 0.00% -530.01% -292.66% -18.29%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 341.70% 2,465.78% 0.00% 0.00% 512.60% 276.48% 17.17%
Return on Equity (ROE)		 -2,399.07% -84.93% -38.14% -42.99% -29.07% -40.81% -24.46% -19.92% 1.52%
Cash Return on Invested Capital (CROIC)		 0.00% -1,008.79% -425.30% 0.00% 0.00% -1,187.17% -557.93% -348.21% 20.07%
Operating Return on Assets (OROA)		 -40.87% -57.36% -32.91% -38.69% -26.47% -35.89% -21.98% -18.00% -0.85%
Return on Assets (ROA)		 -40.87% -57.36% -31.62% -37.60% -26.06% -35.94% -21.33% -15.31% 1.05%
Return on Common Equity (ROCE)		 -2,399.07% -84.93% -38.14% -42.99% -29.07% -40.81% -24.46% -19.92% 1.52%
Return on Equity Simple (ROE_SIMPLE)		 -2,399.07% -42.71% -47.15% -29.60% -25.18% -37.77% -26.68% -20.64% 1.52%
Net Operating Profit after Tax (NOPAT)		 -18 -33 -39 -64 -73 -127 -78 -64 -3.62
NOPAT Margin		 -10,126.53% -7,848.71% -8,351.62% -20,018.90% -145.66% -277.41% -58.22% -36.57% -1.54%
Net Nonoperating Expense Percent (NNEP)		 -14.57% -38.46% -11.17% -12.18% -8.14% -12.25% -7.05% -3.74% 2.64%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -19.25% -16.98% -0.96%
Cost of Revenue to Revenue		 2.31% 0.00% 0.00% 0.00% 0.00% 2.39% 4.23% 8.06% 12.01%
SG&A Expenses to Revenue		 4,028.90% 2,893.78% 2,957.67% 7,024.53% 194.09% 380.52% 146.51% 111.12% 73.16%
R&D to Revenue		 8,401.16% 8,117.22% 8,937.80% 16,624.53% 100.42% 112.13% 33.57% 28.28% 8.84%
Operating Expenses to Revenue		 14,564.16% 11,312.44% 12,318.57% 28,698.43% 308.09% 493.91% 178.94% 144.18% 89.98%
Earnings before Interest and Taxes (EBIT)		 -23 -71 -55 -91 -104 -181 -111 -92 -4.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -71 -54 -90 -103 -177 -110 -92 2.03
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.09 5.80 3.79 6.19 1.51 3.42 3.41
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.73 5.98 3.88 6.30 1.54 3.46 3.45
Price to Revenue (P/Rev)		 0.00 0.00 1,238.08 5,447.28 30.85 65.03 4.58 7.36 5.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223.53
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.45%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 37.55 0.00 0.00 192.08 13.99 34.49 48.80
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,013.23 4,484.95 22.42 54.81 1.68 5.36 3.94
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 457.46
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20.89
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 199.75
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.07 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.07 0.19 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -40.83 -1.18 -0.93 -0.99 -1.03 -1.00 -0.97 -0.94 -0.94
Leverage Ratio		 58.70 1.48 1.21 1.14 1.12 1.14 1.15 1.30 1.45
Compound Leverage Factor		 58.70 1.48 1.16 1.11 1.10 1.13 1.09 1.10 -2.31
Debt to Total Capital		 0.00% 6.64% 16.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 6.64% 16.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 93.36% 83.81% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.17 -0.40 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.28 1.93 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.17 -0.40 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.36 -0.56 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 4.93 2.69 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.36 -0.56 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 6.13 38.60 15.22 25.76 3.57 2.68 3.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 6.86 21.50 18.30 27.90 13.11 12.63 9.60 5.50 4.57
Quick Ratio		 6.86 21.30 17.36 27.13 12.45 11.85 8.74 4.85 4.04
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -79 -43 -44 -65 -154 -81 -75 4.64
Operating Cash Flow to CapEx		 0.00% -164,676.00% -69,744.59% -74,805.88% -951.36% -10,505.80% -27,235.96% -4,660.31% 15,796.44%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -27.17 0.96
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.06 9.18
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.32 9.12
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.13 0.09 0.26 0.34 0.43
Accounts Receivable Turnover		 2.01 4.29 2.84 1.09 0.00 0.00 9.28 9.34 7.76
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.07 0.26 0.44 0.72
Fixed Asset Turnover		 0.00 0.00 12.86 4.75 20.54 9.91 33.23 50.12 77.28
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.04 0.15 0.64 5.94
Days Sales Outstanding (DSO)		 181.45 85.14 128.50 335.73 0.00 0.00 39.35 39.07 47.06
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 5,562.49 1,420.24 831.45 509.96
Days Payable Outstanding (DPO)		 528,428.75 0.00 0.00 0.00 0.00 9,993.84 2,414.55 571.66 61.47
Cash Conversion Cycle (CCC)		 -528,247.30 85.14 128.50 335.73 0.00 -4,431.35 -954.96 298.86 495.55
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -39 7.87 12 -7.42 -15 13 16 27 19
Invested Capital Turnover		 0.00 -0.03 0.05 0.13 -4.48 -46.87 9.23 8.11 10.16
Increase / (Decrease) in Invested Capital		 0.00 47 4.63 -20 -7.54 28 3.03 11 -8.26
Enterprise Value (EV)		 0.00 0.00 469 1,426 1,123 2,499 225 940 927
Market Capitalization		 0.00 0.00 573 1,732 1,546 2,966 614 1,291 1,286
Book Value per Share		 $0.00 $1.97 $1.34 $3.49 $3.65 $3.69 $2.85 $2.63 $2.64
Tangible Book Value per Share		 $0.00 $1.80 $1.19 $3.39 $3.56 $3.63 $2.81 $2.60 $2.61
Total Capital		 0.97 178 134 299 408 479 405 378 377
Total Debt		 0.00 12 22 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 12 22 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -40 -162 -104 -306 -423 -466 -389 -351 -358
Capital Expenditures (CapEx)		 -0.02 0.03 0.07 0.09 7.34 1.50 0.29 0.72 0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.71 -6.36 -0.27 -2.18 -11 6.60 7.04 -2.88 -9.64
Debt-free Net Working Capital (DFNWC)		 34 167 126 304 387 473 396 348 349
Net Working Capital (NWC)		 34 167 126 304 387 473 396 348 349
Net Nonoperating Expense (NNE)		 5.78 38 14 25 30 54 30 14 -9.37
Net Nonoperating Obligations (NNO)		 -40 -158 -100 -306 -423 -466 -389 -351 -358
Total Depreciation and Amortization (D&A)		 1.29 -0.10 1.31 1.17 1.37 3.42 1.13 -0.49 6.71
Debt-free, Cash-free Net Working Capital to Revenue		 -3,297.69% -1,521.53% -58.10% -684.59% -21.75% 14.47% 5.25% -1.64% -4.10%
Debt-free Net Working Capital to Revenue		 19,620.81% 39,976.56% 27,124.62% 95,547.80% 773.04% 1,036.46% 295.78% 198.05% 148.36%
Net Working Capital to Revenue		 19,620.81% 39,976.56% 27,124.62% 95,547.80% 773.04% 1,036.46% 295.78% 198.05% 148.36%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.92) ($0.76) $0.00 ($0.87) ($1.40) ($0.76) ($0.54) $0.04
Adjusted Weighted Average Basic Shares Outstanding		 0.00 84.05M 85.50M 111.80M 127.45M 141.65M 141.92M 143.24M 143.06M
Adjusted Diluted Earnings per Share		 $0.00 ($0.92) ($0.76) $0.00 ($0.87) ($1.40) ($0.76) ($0.54) $0.04
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 84.05M 85.50M 111.80M 127.45M 141.65M 141.92M 143.24M 146.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.92) ($0.76) $0.00 ($0.87) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 84.05M 85.50M 111.80M 118.47M 129.37M 142.58M 144.62M 137.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -33 -39 -64 -73 -127 -78 -64 14
Normalized NOPAT Margin		 -10,126.53% -7,848.71% -8,351.62% -20,018.90% -145.66% -277.41% -58.22% -36.57% 6.05%
Pre Tax Income Margin		 -13,465.32% -16,935.89% -11,448.38% -27,748.74% -205.06% -395.15% -79.35% -44.14% 3.17%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -33.04 -0.97
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -23.13 -0.75
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -33.30 -1.03
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -23.39 -0.81
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 699.57%

Quarterly Metrics And Ratios for Aurinia Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 21.50% 59.12% 47.19% -2.27% 58.59% 46.19% 37.83% 24.32% 32.76% 24.18% 22.41%
EBITDA Growth		 7.93% 14.70% 47.22% -57.24% 4.79% 63.11% 101.11% 192.85% 100.76% 307.09% 10,819.02%
EBIT Growth		 14.08% 21.90% 55.07% -71.21% -5.60% 55.20% 90.64% 172.24% 94.38% 264.85% 1,427.36%
NOPAT Growth		 14.08% 21.90% 55.07% -71.21% -5.60% 55.20% 93.47% 200.01% 90.21% 325.77% 2,738.38%
Net Income Growth		 21.84% 30.36% 67.64% -49.59% -3.18% 58.98% 106.28% 206.72% 105.32% 317.17% 2,879.64%
EPS Growth		 25.00% 33.33% 68.00% -50.00% -5.56% 61.11% 112.50% 211.11% 0.00% 328.57% 1,500.00%
Operating Cash Flow Growth		 140.31% 32.25% 89.86% 13.57% 36.96% 41.28% 660.62% 228.26% 110.41% 106.99% 179.25%
Free Cash Flow Firm Growth		 55.37% 56.55% 57.16% 56.82% -40.92% 2.20% 133.06% 241.84% 119.47% 216.46% 382.38%
Invested Capital Growth		 23.30% -1.69% 29.80% 14.12% 69.92% 36.33% -18.37% -26.47% -30.30% -5.27% -40.58%
Revenue Q/Q Growth		 -49.02% 21.01% 20.59% 31.38% -17.28% 11.55% 13.70% 18.50% -11.66% 4.34% 12.08%
EBITDA Q/Q Growth		 -225.11% -6.93% 41.42% 22.78% -96.87% 58.57% 101.77% 6,348.78% -98.38% 11,136.92% -6.92%
EBIT Q/Q Growth		 -195.82% -5.28% 45.34% -0.58% -82.46% 55.34% 88.58% 876.47% -114.21% 1,408.99% -8.07%
NOPAT Q/Q Growth		 -195.82% -5.28% 45.34% -0.58% -82.46% 55.34% 92.03% 1,640.45% -117.86% 1,130.14% -6.90%
Net Income Q/Q Growth		 -189.75% -0.61% 56.15% -17.01% -99.86% 60.00% 106.72% 1,887.53% -90.04% 1,533.59% -7.84%
EPS Q/Q Growth		 -200.00% 0.00% 55.56% -12.50% -111.11% 63.16% 114.29% 900.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 168.03% -403.06% 91.08% -369.82% 207.80% -229.95% 185.19% 7.49% 76.84% -95.68% 3,303.15%
Free Cash Flow Firm Q/Q Growth		 45.50% 10.97% -3.24% 13.79% -77.83% 38.21% 134.89% 269.92% -75.59% 269.60% 44.54%
Invested Capital Q/Q Growth		 -65.70% 79.96% 44.00% 28.40% -48.93% 44.38% -13.78% 15.65% -51.59% 96.24% -45.91%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 95.21% 98.78% 96.23% 87.58% 88.04% 84.59% 84.42% 91.10% 90.73% 86.27% 89.84%
EBITDA Margin		 -103.53% -91.48% -44.44% -26.12% -62.16% -23.08% 0.36% 19.51% 0.36% 38.50% 31.97%
Operating Margin		 -98.82% -85.98% -38.97% -29.83% -65.80% -26.35% -2.65% 17.33% -2.79% 34.97% 28.69%
EBIT Margin		 -98.82% -85.98% -38.97% -29.83% -65.80% -26.35% -2.65% 17.33% -2.79% 34.97% 28.69%
Profit (Net Income) Margin		 -91.60% -76.16% -27.70% -24.67% -59.60% -21.37% 1.26% 21.17% 2.39% 37.37% 30.73%
Tax Burden Percent		 103.39% 101.69% 94.71% 102.27% 101.74% 107.38% 48.85% 96.91% 121.82% 95.87% 97.10%
Interest Burden Percent		 89.65% 87.11% 75.04% 80.85% 89.02% 75.53% -97.69% 126.04% -70.28% 111.45% 110.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 51.15% 3.09% -21.82% 4.13% 2.90%
Return on Invested Capital (ROIC)		 -638.14% -303.40% -118.67% -66.23% -373.34% -103.46% -7.09% 79.92% -34.52% 216.35% 267.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 -636.65% -302.00% -118.63% -65.66% -371.69% -103.03% -7.52% 79.06% -35.50% 215.59% 267.17%
Return on Net Nonoperating Assets (RNNOA)		 615.74% 281.02% 107.92% 57.59% 351.14% 93.65% 6.77% -69.67% 33.32% -192.31% -246.52%
Return on Equity (ROE)		 -22.41% -22.39% -10.75% -8.64% -22.20% -9.81% -0.32% 10.25% -1.20% 24.05% 21.28%
Cash Return on Invested Capital (CROIC)		 -557.93% -246.28% -184.47% -139.14% -348.21% -185.36% -92.31% -18.90% 20.07% 81.04% 237.46%
Operating Return on Assets (OROA)		 -26.12% -26.33% -12.10% -9.08% -22.67% -10.41% -1.02% 6.92% -1.19% 16.93% 14.54%
Return on Assets (ROA)		 -24.21% -23.33% -8.60% -7.51% -20.53% -8.45% 0.49% 8.45% 1.02% 18.09% 15.58%
Return on Common Equity (ROCE)		 -22.41% -22.39% -10.75% -8.64% -22.20% -9.81% -0.32% 10.25% -1.20% 24.05% 21.28%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -24.78% -18.54% -19.70% 0.00% -17.40% -13.81% -5.81% 0.00% 11.38% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -21 -11 -11 -21 -9.28 -0.74 11 -2.03 21 20
NOPAT Margin		 -69.18% -60.18% -27.28% -20.88% -46.06% -18.44% -1.29% 16.80% -3.40% 33.53% 27.85%
Net Nonoperating Expense Percent (NNEP)		 -1.49% -1.41% -0.05% -0.58% -1.65% -0.43% 0.43% 0.86% 0.98% 0.76% 0.62%
Return On Investment Capital (ROIC_SIMPLE)		 -4.85% - - - -5.50% - - - -0.54% 5.98% 5.82%
Cost of Revenue to Revenue		 4.79% 1.22% 3.77% 12.42% 11.96% 15.41% 15.58% 8.91% 9.27% 13.73% 10.16%
SG&A Expenses to Revenue		 166.95% 145.67% 113.46% 87.61% 111.04% 94.82% 78.57% 62.51% 61.86% 32.56% 37.16%
R&D to Revenue		 34.71% 38.24% 30.49% 24.96% 22.68% 11.04% 7.13% 4.50% 13.54% 9.19% 10.62%
Operating Expenses to Revenue		 194.03% 184.75% 135.20% 117.42% 153.84% 110.94% 87.07% 73.76% 93.51% 51.30% 61.15%
Earnings before Interest and Taxes (EBIT)		 -28 -30 -16 -16 -30 -13 -1.51 12 -1.67 22 20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -31 -18 -14 -28 -12 0.21 13 0.21 24 22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.51 4.00 3.53 2.84 3.42 2.00 2.24 2.70 3.41 3.15 3.41
Price to Tangible Book Value (P/TBV)		 1.54 4.07 3.58 2.88 3.46 2.03 2.27 2.73 3.45 3.19 3.45
Price to Revenue (P/Rev)		 4.58 10.64 8.65 7.02 7.36 3.76 3.94 4.76 5.47 4.47 4.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223.53 27.71 18.87
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.45% 3.61% 5.30%
Enterprise Value to Invested Capital (EV/IC)		 13.99 41.60 24.86 14.53 34.49 10.15 14.32 17.82 48.80 21.22 41.11
Enterprise Value to Revenue (EV/Rev)		 1.68 8.18 6.46 4.88 5.36 2.09 2.35 3.17 3.94 3.20 3.19
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 457.46 21.00 13.85
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 26.02 15.94
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27.30 16.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.47 20.89 12.31 8.95
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 199.75 25.48 12.91
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.93 -0.91 -0.88 -0.94 -0.91 -0.90 -0.88 -0.94 -0.89 -0.92
Leverage Ratio		 1.15 1.14 1.26 1.28 1.30 1.29 1.42 1.42 1.45 1.44 1.47
Compound Leverage Factor		 1.03 1.00 0.95 1.03 1.16 0.98 -1.38 1.78 -1.02 1.60 1.62
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.16 13.64 3.97 2.74 3.05 1.21 1.69 2.77 3.25 3.19 3.06
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.60 10.08 6.75 5.77 5.50 5.60 5.33 5.60 4.57 5.93 5.23
Quick Ratio		 8.74 9.05 6.00 5.09 4.85 4.91 4.63 4.90 4.04 5.16 4.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -20 -21 -18 -32 -20 6.90 26 6.23 23 33
Operating Cash Flow to CapEx		 7,798.51% -9,126.80% -1,596.61% 0.00% 4,786.62% 0.00% 0.00% 0.00% 10,716.73% 7,647.06% 45,143.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -321.02 -12.85 -24.42 -15.41 5.76 21.12 5.44 21.58 29.79
Operating Cash Flow to Interest Expense		 0.00 0.00 -43.48 -9.48 10.93 -14.50 13.22 14.10 26.28 1.22 39.61
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -46.20 -9.41 10.70 -14.50 13.22 14.10 26.03 1.20 39.52
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.26 0.31 0.31 0.30 0.34 0.40 0.39 0.40 0.43 0.48 0.51
Accounts Receivable Turnover		 9.28 7.44 8.50 3.99 9.34 7.98 9.20 5.92 7.76 7.14 7.93
Inventory Turnover		 0.26 0.20 0.20 0.35 0.44 0.60 0.80 0.79 0.72 0.68 0.64
Fixed Asset Turnover		 33.23 35.92 40.88 43.80 50.12 54.38 61.89 69.05 77.28 85.66 95.21
Accounts Payable Turnover		 0.15 0.17 0.16 0.22 0.64 0.50 0.59 0.52 5.94 1.07 0.91
Days Sales Outstanding (DSO)		 39.35 49.04 42.94 91.58 39.07 45.72 39.67 61.64 47.06 51.11 46.04
Days Inventory Outstanding (DIO)		 1,420.24 1,816.26 1,859.28 1,048.99 831.45 607.56 455.90 464.74 509.96 539.63 571.11
Days Payable Outstanding (DPO)		 2,414.55 2,138.15 2,323.54 1,667.71 571.66 732.71 619.42 708.66 61.47 342.09 399.93
Cash Conversion Cycle (CCC)		 -954.96 -272.85 -421.33 -527.13 298.86 -79.42 -123.85 -182.28 495.55 248.65 217.21
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 16 29 42 53 27 39 34 39 19 37 20
Invested Capital Turnover		 9.23 5.04 4.35 3.17 8.11 5.61 5.48 4.76 10.16 6.45 9.61
Increase / (Decrease) in Invested Capital		 3.03 -0.50 9.55 6.61 11 10 -7.64 -14 -8.26 -2.08 -14
Enterprise Value (EV)		 225 1,201 1,034 776 940 399 486 699 927 791 829
Market Capitalization		 614 1,563 1,385 1,114 1,291 719 817 1,048 1,286 1,104 1,144
Book Value per Share		 $2.85 $2.74 $2.74 $2.73 $2.63 $2.50 $2.55 $2.71 $2.64 $2.55 $2.48
Tangible Book Value per Share		 $2.81 $2.70 $2.70 $2.70 $2.60 $2.46 $2.52 $2.68 $2.61 $2.52 $2.45
Total Capital		 405 390 392 392 378 359 365 388 377 350 335
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -389 -362 -351 -338 -351 -320 -331 -349 -358 -313 -315
Capital Expenditures (CapEx)		 0.13 0.35 0.18 -0.11 0.30 0.00 0.00 0.00 0.28 0.02 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.04 20 3.53 15 -2.88 7.26 2.29 13 -9.64 24 16
Debt-free Net Working Capital (DFNWC)		 396 382 354 353 348 327 333 362 349 337 331
Net Working Capital (NWC)		 396 382 354 353 348 327 333 362 349 337 331
Net Nonoperating Expense (NNE)		 6.38 5.50 0.17 2.06 6.10 1.47 -1.46 -2.96 -3.46 -2.40 -2.01
Net Nonoperating Obligations (NNO)		 -389 -362 -351 -338 -351 -320 -331 -349 -358 -313 -315
Total Depreciation and Amortization (D&A)		 -1.34 -1.89 -2.27 2.03 1.64 1.64 1.72 1.47 1.88 2.20 2.30
Debt-free, Cash-free Net Working Capital to Revenue		 5.25% 13.67% 2.21% 9.24% -1.64% 3.79% 1.10% 5.95% -4.10% 9.89% 5.99%
Debt-free Net Working Capital to Revenue		 295.78% 259.92% 221.24% 221.95% 198.05% 170.93% 160.67% 164.21% 148.36% 136.42% 127.14%
Net Working Capital to Revenue		 295.78% 259.92% 221.24% 221.95% 198.05% 170.93% 160.67% 164.21% 148.36% 136.42% 127.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.18) ($0.18) ($0.08) ($0.09) ($0.19) ($0.07) $0.01 $0.10 $0.00 $0.17 $0.16
Adjusted Weighted Average Basic Shares Outstanding		 141.92M 142.64M 142.78M 142.85M 143.24M 144.01M 143.33M 143.05M 143.06M 138.92M 134.87M
Adjusted Diluted Earnings per Share		 ($0.18) ($0.18) ($0.08) ($0.09) ($0.19) ($0.07) $0.01 $0.10 $0.00 $0.16 $0.16
Adjusted Weighted Average Diluted Shares Outstanding		 141.92M 142.64M 142.78M 142.85M 143.24M 144.01M 144.11M 145.65M 146.19M 143.20M 137.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 142.58M 143.03M 143.42M 143.61M 144.62M 143.02M 142.99M 143.18M 137.34M 135.10M 131.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -21 -11 -11 -21 -4.60 -0.31 11 9.58 22 20
Normalized NOPAT Margin		 -69.18% -60.18% -27.28% -20.88% -46.06% -9.14% -0.54% 16.80% 16.00% 35.88% 28.01%
Pre Tax Income Margin		 -88.59% -74.89% -29.24% -24.12% -58.58% -19.90% 2.58% 21.85% 1.96% 38.98% 31.65%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -248.77 -11.62 -22.65 -10.33 -1.26 9.73 -1.46 20.48 17.98
NOPAT to Interest Expense		 0.00 0.00 -174.14 -8.13 -15.86 -7.23 -0.62 9.43 -1.77 19.63 17.46
EBIT Less CapEx to Interest Expense		 0.00 0.00 -251.49 -11.54 -22.88 -10.33 -1.26 9.73 -1.70 20.46 17.89
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -176.86 -8.06 -16.08 -7.23 -0.62 9.43 -2.02 19.61 17.37
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 699.57% 187.88% 183.54%

Key Financial Trends

Aurinia Pharmaceuticals (NASDAQ: AUPH) has demonstrated a significant turnaround in its financial performance over the last four years, with a particularly strong improvement in 2025 Q2. Here are the key trends and highlights from their quarterly financial statements:

  • Net income turned positive in 2024 and has continued to improve, reaching $21.5 million in Q2 2025 compared to a loss of -$26.9 million in Q4 2023 and even larger losses in earlier periods.
  • Operating revenue has steadily increased from $28.1 million in Q2 2022 to $70.0 million in Q2 2025, reflecting strong top-line growth.
  • Gross profit has grown significantly, from approximately $26.6 million in Q2 2022 to about $62.9 million in Q2 2025, with the cost of revenue remaining relatively stable.
  • Operating expenses, while still substantial, decreased recently to $42.8 million in Q2 2025 from peaks above $55 million in 2023, indicating better expense control.
  • Positive operating income of $20.1 million in Q2 2025 contrasts with operating losses in previous years, indicating the company is moving toward sustainable profitability.
  • Cash and short-term investments combined remain robust, with total current assets around $409M (Q2 2025), supporting liquidity and operations.
  • Repurchases of common equity continue, indicating management confidence and returning value to shareholders, although these also use significant cash resources.
  • Depreciation and amortization expenses have remained stable, with slight fluctuations, indicating consistent capital asset usage and intangible asset amortization.
  • The company has consistently reported restructuring charges in some quarters, though amounts have varied from minimal to over $15 million in certain periods, reflecting ongoing business adjustments.
  • Changes in operating assets and liabilities have sometimes led to positive and sometimes negative cash flow impacts, showing typical working capital management fluctuations.
  • The company reported net losses consistently before 2024, with losses as large as -$35.5 million in Q2 2022 and -$26.9 million in Q4 2023, indicating a history of unprofitable operations.
  • Significant investment purchases have resulted in negative investing cash flows in many quarters, indicating continued investment in property, plant, equipment, and securities.
  • Financial liabilities, including accrued expenses and accounts payable, have increased notably, rising from approximately $61.6 million in Q2 2024 to about $78.3 million in Q2 2025, potentially impacting liquidity.
  • Despite recent profitability, interest expense has remained present each quarter, reducing net income and cash flow.

Summary: Aurinia Pharmaceuticals has made substantial progress from operating losses and negative earnings in 2022 and 2023 to achieving positive net income and operating income in early 2025 quarters. Revenue growth and gross profit improvements have been critical to this turnaround. The company maintains a strong cash position but still invests heavily in growth initiatives and continues to manage liabilities. Retail investors should note the positive profitability trend but remain mindful of the company's history of losses and ongoing investment outlays.

08/08/25 03:05 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

When does Aurinia Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Aurinia Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Aurinia Pharmaceuticals' net income changed over the last 8 years?

Aurinia Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $5.75 million in 2024, falling from -$23.30 million in 2016. The previous period was -$78.02 million in 2023. Check out Aurinia Pharmaceuticals' forecast to explore projected trends and price targets.

What is Aurinia Pharmaceuticals' operating income?
Aurinia Pharmaceuticals' total operating income in 2024 was -$4.69 million, based on the following breakdown:
  • Total Gross Profit: $206.89 million
  • Total Operating Expenses: $211.57 million
How has Aurinia Pharmaceuticals' revenue changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' total revenue changed from $173 thousand in 2016 to $235.13 million in 2024, a change of 135,815.0%.

How much debt does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals' total liabilities were at $173.17 million at the end of 2024, a 1.8% increase from 2023, and a 722.8% increase since 2016.

How much cash does Aurinia Pharmaceuticals have?

In the past 8 years, Aurinia Pharmaceuticals' cash and equivalents has ranged from $39.65 million in 2016 to $306.02 million in 2019, and is currently $83.43 million as of their latest financial filing in 2024.

How has Aurinia Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' book value per share changed from 0.00 in 2016 to 2.64 in 2024, a change of 263.6%.


Related Companies

This page (NASDAQ:AUPH) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsored
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...
Paradigm Press | Sponsored
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...
Brownstone Research | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
How high will gold surge?
Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...
Weiss Ratings | Sponsored
Shocked one of my clients with this
Trump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...
Altimetry | Sponsored
Critical AI announcement set to ignite AI 2.0
While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly tak...
Timothy Sykes | Sponsored
Trump’s new nightmare
According to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...
Porter & Company | Sponsored